Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Medtronic’s Renal Denervation System Will Get Parallel Treatment From FDA And CMS

Mar 11 2013

• By Reed Miller

Related Content

<i>Cypher</i>’s Impact On Regulatory, Reimbursement Landscape

Jun 20 2011

Parallel Reviews Should Lead To Local Coverage, Coding Decisions, Firms Say

Jan 03 2011

Calling All Innovators: FDA And CMS Seek Candidates For Parallel Review Pilot

Oct 17 2011

FDA And CMS Agree To Share Data Routinely In Step Toward Parallel Reviews

Jun 28 2010

CMS Policy Sets Boundaries On Transcatheter Valve Procedure

May 07 2012

Ablating Blood Pressure: Ardian's RF Catheter Hits Hypertension Endpoint

Nov 22 2010

CDRH Entrepreneurs Take Two: Streamlining Data Collection And The Path To Reimbursement

Oct 22 2012

Boston Scientific Enters Renal Denervation Market Via Vessix Acquisition

Nov 12 2012

St. Jude Plans Trial To Study Renal Denervation Outcomes

Feb 25 2013

With Trial Approval, Medtronic Aims For <i>Symplicity</i> RF Catheter Launch In 2014

Jul 18 2011

Related Companies

Medtronic plc

Johnson & Johnson

Cardinal Health, Inc.

Edwards Lifesciences Corp.

Covidien plc

Boston Scientific Corporation

Abbott

Additional Topics

Regulation Reimbursement

More from Market Access

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window